PL3917521T3 - Postacie stałe promotora spinogenezy - Google Patents

Postacie stałe promotora spinogenezy

Info

Publication number
PL3917521T3
PL3917521T3 PL20747738.1T PL20747738T PL3917521T3 PL 3917521 T3 PL3917521 T3 PL 3917521T3 PL 20747738 T PL20747738 T PL 20747738T PL 3917521 T3 PL3917521 T3 PL 3917521T3
Authority
PL
Poland
Prior art keywords
spinogenesis
promoter
solid forms
solid
forms
Prior art date
Application number
PL20747738.1T
Other languages
English (en)
Inventor
Stella T. SARRAF
Elizabeth Büchler VADAS
Original Assignee
Spinogenix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinogenix, Inc. filed Critical Spinogenix, Inc.
Publication of PL3917521T3 publication Critical patent/PL3917521T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL20747738.1T 2019-01-31 2020-01-30 Postacie stałe promotora spinogenezy PL3917521T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799644P 2019-01-31 2019-01-31
PCT/US2020/015967 WO2020160332A1 (en) 2019-01-31 2020-01-30 Solid forms of a promoter of spinogenesis

Publications (1)

Publication Number Publication Date
PL3917521T3 true PL3917521T3 (pl) 2025-10-20

Family

ID=71841255

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20747738.1T PL3917521T3 (pl) 2019-01-31 2020-01-30 Postacie stałe promotora spinogenezy

Country Status (13)

Country Link
US (1) US12486287B2 (pl)
EP (2) EP3917521B1 (pl)
JP (2) JP7572361B2 (pl)
CN (2) CN113727710A (pl)
AU (2) AU2020214830B2 (pl)
CA (1) CA3128280A1 (pl)
ES (1) ES3032326T3 (pl)
HR (1) HRP20250780T1 (pl)
HU (1) HUE072464T2 (pl)
PL (1) PL3917521T3 (pl)
RS (1) RS67123B1 (pl)
SM (1) SMT202500291T1 (pl)
WO (1) WO2020160332A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071525A1 (en) 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds
US12486287B2 (en) 2019-01-31 2025-12-02 Spinogenix, Inc. Solid forms of a promoter of spinogenesis
JP2024507224A (ja) * 2021-02-22 2024-02-16 スピノジェニックス， インコーポレイテッド 脊髄傷害または損傷を処置する方法
US20240180920A1 (en) * 2021-03-23 2024-06-06 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
EP4687886A1 (en) * 2023-04-03 2026-02-11 Spinogenix, Inc. Methods of dosing spinogenic compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
SI1334091T1 (sl) 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
ZA200703998B (en) 2004-11-17 2008-11-26 Ares Trading Sa Benzothiazole formulations and use thereof
US7666886B2 (en) 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR101395146B1 (ko) 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
US20160000762A1 (en) 2013-02-27 2016-01-07 The Regents Of The University Of California Improving cognitive function
CN103554482B (zh) 2013-10-29 2017-01-25 西安近代化学研究所 一种端羟基聚乙二醇对甲苯磺酸酯的合成方法
CA2940144C (en) 2014-02-20 2023-06-13 Cornell University Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
HK1255468A1 (zh) 2016-01-05 2019-08-16 The Regents Of The University Of California 苯并噻唑两亲物
TWI586367B (zh) 2016-03-28 2017-06-11 蔡懷楨 磷酸甘油酯激酶增加神經突生長及／或治療神經性疾病的用途
WO2019005682A1 (en) 2017-06-26 2019-01-03 Spinogenix, Inc. USE OF BENZOTHIAZOLE AMPHIPHILES TO TREAT TRAUMATIC BRAIN INJURY
CA3071525A1 (en) * 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds
EP3843846A4 (en) 2018-08-27 2022-09-07 Spinogenix, Inc. FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS
US12486287B2 (en) 2019-01-31 2025-12-02 Spinogenix, Inc. Solid forms of a promoter of spinogenesis

Also Published As

Publication number Publication date
US12486287B2 (en) 2025-12-02
JP2022523106A (ja) 2022-04-21
RS67123B1 (sr) 2025-09-30
EP3917521A4 (en) 2022-10-26
EP4620527A3 (en) 2025-12-17
EP4620527A2 (en) 2025-09-24
AU2020214830B2 (en) 2025-10-23
HRP20250780T1 (hr) 2025-09-12
AU2026200464A1 (en) 2026-02-12
CN113727710A (zh) 2021-11-30
CA3128280A1 (en) 2020-08-06
SMT202500291T1 (it) 2025-09-12
EP3917521B1 (en) 2025-05-28
EP3917521C0 (en) 2025-05-28
HUE072464T2 (hu) 2025-11-28
WO2020160332A1 (en) 2020-08-06
US20220106330A1 (en) 2022-04-07
JP2025004201A (ja) 2025-01-14
ES3032326T3 (en) 2025-07-17
JP7572361B2 (ja) 2024-10-23
EP3917521A1 (en) 2021-12-08
CN119490468A (zh) 2025-02-21
AU2020214830A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
RS67123B1 (sr) Čvrsti oblici promotera spinogeneze
ZA202207543B (en) Pyridazinyl-thiazolecarboxamide compound
IL291172A (en) new compounds
GB202103470D0 (en) Promoter
GB202011800D0 (en) Compound
GB201905233D0 (en) A consumable
GB201917867D0 (en) Polymorphs
GB201912404D0 (en) New compounds
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
GB201903499D0 (en) Minimal promoter
GB2597010B (en) Mooring assembly
CA195589S (en) Part of a trampoline
GB202109231D0 (en) Promoter
GB202304841D0 (en) Promoter
GB202009410D0 (en) Promoter design
GB201905220D0 (en) Forskolin-inducible promoters
GB201905219D0 (en) Hypoxia-enducible promoters
GB2580745B (en) Life extension assembly for structures
GB201918032D0 (en) New polymorphs
GB202000007D0 (en) A searchlight
GB201910664D0 (en) Novel forms of compound
GB202005473D0 (en) Forskolin-inducible promoters
GB2588828B (en) Balustrade
GB201906531D0 (en) Acoustic liner
CA189948S (en) Ring